Category Research

Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…

Read MoreImfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

Enhertu + THP Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11

Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab, and pertuzumab (THP), has shown a significantly improved safety profile…

Read MoreEnhertu + THP Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11

Breztri Achieves Primary Endpoints in Pivotal Phase III KALOS and LOGOS Trials for Asthma

AstraZeneca’s Breztri Achieves Primary Endpoints in KALOS and LOGOS Phase III Trials, Marking a Significant Advance in the Treatment of Uncontrolled Asthma AstraZeneca announced encouraging high-level results from its pivotal Phase III KALOS and LOGOS clinical trials evaluating Breztri Aerosphere…

Read MoreBreztri Achieves Primary Endpoints in Pivotal Phase III KALOS and LOGOS Trials for Asthma
Vaccine

Vaccine Study Shows Fewer Side Effects with PharmaJet Needle-Free Delivery

Vaccine Study Shows Fewer Side Effects with PharmaJet Needle-Free Delivery PharmaJet®, a company committed to advancing the performance, safety, and effectiveness of injectable vaccines and therapies through innovative needle-free injection technology, has announced the publication of a significant new study…

Read MoreVaccine Study Shows Fewer Side Effects with PharmaJet Needle-Free Delivery
Biosciences

Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis

Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis Predicta Biosciences, a precision oncology company, has officially launched its first Laboratory Developed Test (LDT), GenoPredicta, a cutting-edge diagnostic tool designed for use in both blood and bone marrow…

Read MorePredicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis
Pilatus

Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer

Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer Pilatus Biosciences, a biotechnology company dedicated to developing next-generation immunometabolic therapies for cancer, has announced the publication of a pivotal preclinical study in Cancer Discovery, a leading peer-reviewed…

Read MorePilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer